Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E.
Other stock markets
 03:59:45 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.5 CAD +2.04% Intraday chart for Oncolytics Biotech Inc. +4.90% -16.20%
Apr. 11 Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA CI
Apr. 11 Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA
CI
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
MT
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain
MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million
MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
CI
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort
MT
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
CI
Oncolytics Biotech Brief: Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort
MT
Oncolytics Biotech Provides Outlook for 2024
MT
Oncolytics Biotech Brief: Recapping 2023 Accomplishments, Providing Outlook for 2024
MT
Oncolytics Biotech and SOLTI Present "Positive" Translational Data at SABCS
MT
Oncolytics Biotech Brief: Oncolytics and SOLTI Present "Positive" Translational Data at SABCS
MT
Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
CI
Oncolytics Biotech Brief: Providing Update on Pancreatic Cancer Program for Pelareorep
MT
Oncolytics Biotech Inc. Provides Update on Pancreatic Cancer Program for Pelareorep
CI
Oncolytics Biotech, SOLTI Present Further Positive Pelareorep Translational Data at SITC
MT
Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. News Oncolytics Biotech Inc.
  5. Highlights